Skip Navigation

European Heart Journal 2003 24(8):685-689; doi:10.1016/S0195-668X(03)00085-X
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia

James Shepherd*

Institute of Biochemistry, Royal Infirmary, North Glasgow University Hospitals NHS Trust, Glasgow G4 0SF, UK

* Tel.: +44-141-211-4628; fax: +44-141-553-1703
E-mail address: jshepherd@gri-biochem.org.uk

The first 150 words of the full text of this article appear below.

See doi:10.1016/S1095-668X(02)00807-2for the articles to which this editorial refers

Every day we consume approximately 300mg of cholesterol and its esters and 100g of triglyceride in our diet.1 This mixes in the intestinal lumen with about 900mg of biliary cholesterol and thereafter the total package is reduced by digestion to free cholesterol, fatty acids and mono- and diglycerides which become incorporated, through the detergent effects of bile acids, into water soluble micellesfor transport to absorption sites on the luminal surfaces of small intestinal enterocytes (Fig. 1). Triglyceride absorption is virtually complete whereas only about 50% of the cholesterol finds its way into the intestinal mucosa, the remainder being lost in the faeces. Within the enterocyte, cholesteryl esters are rapidly reconstructed by the action of the enzyme acyl Coenzyme A cholesterol acyltransferase (ACAT) and incorporated, with triglyceride, into large lipid-rich chylomicron particles containing about 1% protein. These appear in abundance . . . [Full Text of this Article]

1. Modulation of cholesterol absorption: serendipity takes a hand

2. Tomorrow's world: dual therapy for hypercholesterolaemia with cholesterol absorption and synthesis inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia
R.H. Knopp, H. Gitter, T. Truitt, H. Bays, C.V. Manion, L.J. Lipka, A.P. LeBeaut, R. Suresh, B. Yang, E.P. Veltri, and for the Ezetimibe Study Group
EHJ 2003 24: 729-741. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
R. Cangemi, L. Loffredo, R. Carnevale, L. Perri, M. P. Patrizi, V. Sanguigni, P. Pignatelli, and F. Violi
Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E
Eur. Heart J., January 1, 2008; 29(1): 54 - 62.
[Abstract] [Full Text] [PDF]